ST Spyre Therapeutics, Inc. Stock: price and management transactions · United States · SEC (Form 4)Follow the Spyre Therapeutics, Inc. stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €8bn. The latest transaction was filed on 3 September 2026 (Levée d'options). Among the most active insiders: Burrows Scott L. The full history is openly available.
Analyst consensus: bullish or bearish? Analysts rate Spyre Therapeutics, Inc. Strong Buy (bullish), based on 14 analysts. Average price target: US$119.71.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 September 2026
All Executives80 Thresholds0 Prospectus0 Other0
Declarations 80 total
◇ Chief Financial Officer · Executives · 1 Sept 2026
7,500 shares @ US$14.50 Common Stock SEC:0001636282-26-000109:0
▼ Chief Financial Officer · Executives · 1 Sept 2026
900 shares @ US$86.25 Common Stock SEC:0001636282-26-000109:1
▼ Chief Financial Officer · Executives · 1 Sept 2026
4,384 shares @ US$87.11 Common Stock SEC:0001636282-26-000109:2
▼ Chief Financial Officer · Executives · 1 Sept 2026
2,016 shares @ US$88.03 Common Stock SEC:0001636282-26-000109:3
▼ Chief Financial Officer · Executives · 1 Sept 2026
200 shares @ US$89.04 Common Stock SEC:0001636282-26-000109:4
▼ Chief Financial Officer · Executives · 2 Sept 2026
18,232 shares @ US$89.35 Common Stock SEC:0001636282-26-000109:5
◇ See Remarks · Executives · 1 Sept 2026
27,999 shares @ US$14.50 Common Stock SEC:0001636282-26-000111:0
▼ See Remarks · Executives · 1 Sept 2026
4,845 shares @ US$86.40 Common Stock SEC:0001636282-26-000111:1
▼ See Remarks · Executives · 1 Sept 2026
16,548 shares @ US$87.20 Common Stock SEC:0001636282-26-000111:2
▼ See Remarks · Executives · 1 Sept 2026
6,206 shares @ US$88.17 Common Stock SEC:0001636282-26-000111:3
▼ See Remarks · Executives · 1 Sept 2026
400 shares @ US$89.38 Common Stock SEC:0001636282-26-000111:4
◇ See Remarks · Executives · 2 Sept 2026
400 shares @ US$14.50 Common Stock SEC:0001636282-26-000111:5
▼ See Remarks · Executives · 2 Sept 2026
400 shares @ US$90.00 Common Stock SEC:0001636282-26-000111:6
◇ Director · Executives · 7 Aug 2026
5,000 shares @ US$10.39 0.0006% mcap 1.9% of flow Common Stock SEC:0001636282-26-000102:0
▼ Director · Executives · 7 Aug 2026
5,000 shares @ US$104.47 0.0057% mcap 19.2% of flow Common Stock SEC:0001636282-26-000102:1
▼ Director · Executives · 7 Aug 2026
10,000 shares @ US$104.68 0.012% mcap 38.4% of flow Common Stock SEC:0001636282-26-000102:3
▼ Director · Executives · 7 Aug 2026
8,000 shares @ US$104.38 0.0092% mcap 30.6% of flow Common Stock SEC:0001636282-26-000102:2
▼ Chief Executive Officer · Executives · 3 Aug 2026
1,392 shares @ US$96.82 0.0016% mcap 2.8% of flow Common Stock SEC:0001636282-26-000099:3
▼ Chief Executive Officer · Executives · 3 Aug 2026
800 shares @ US$93.97 0.0009% mcap 1.6% of flow Common Stock SEC:0001636282-26-000099:0
◇ Chief Financial Officer · Executives · 3 Aug 2026
7,500 shares @ US$14.50 0.0013% mcap 3.3% of flow Common Stock SEC:0001636282-26-000100:0
▼ Chief Financial Officer · Executives · 3 Aug 2026
5,100 shares @ US$95.21 0.0059% mcap 14.6% of flow Common Stock SEC:0001636282-26-000100:1
▼ Chief Financial Officer · Executives · 3 Aug 2026
2,300 shares @ US$96.30 0.0027% mcap 6.7% of flow Common Stock SEC:0001636282-26-000100:2
▼ Chief Financial Officer · Executives · 3 Aug 2026
100 shares @ US$97.10 0.0001% mcap 0.3% of flow Common Stock SEC:0001636282-26-000100:3
▼ Chief Executive Officer · Executives · 3 Aug 2026
7,157 shares @ US$95.10 0.0083% mcap 14.1% of flow Common Stock SEC:0001636282-26-000099:1
▼ Chief Executive Officer · Executives · 3 Aug 2026
5,635 shares @ US$95.93 0.0066% mcap 11.2% of flow Common Stock SEC:0001636282-26-000099:2
25 of 80 declarations
Load more (55 remaining) 关于 Spyre Therapeutics, Inc. Spyre Therapeutics, Inc. 是一家专注于开发严重疾病创新疗法的公司。该公司在XNAS市场上市。